Gerresheimer announces strong results for the financial year 2023

Gerresheimer AG, a global partner to the pharmaceutical, biotechnology, and cosmetic industries, confirms its profitable growth for the fiscal year 2023 with an organic revenue increase of 10.4% and a significant rise in adjusted EBITDA by 17.5%. Revenues reached 1.99 billion euros, compared to 1.82 billion in 2022, while adjusted EBITDA was 404.5 million euros, up from 354.2 million in 2022. The adjusted EBITDA margin organically increased by 120 basis points, reaching 20.8%, benefiting from a favorable product mix, including innovative solutions for sensitive biopharmaceuticals.

With a strong order book and the expansion of its production capacities at the international level, Gerresheimer is well positioned to maintain its growth momentum. The company plans to continue on this profitable path in the coming years, with a forecast of organic revenue growth between 5% and 10% for the fiscal year 2024, and an expected growth in adjusted EBITDA between 430 and 450 million euros. The company is proposing a dividend of 1.25 euros per share for the financial year 2023, underlining its confidence in the sustainability of its growth.